Fintel reports that on February 4, 2025, Piper Sandler downgraded their outlook for Amphastar Pharmaceuticals (NasdaqGS:AMPH) ...

Piper Sandler downgraded Amphastar (AMPH) to Neutral from Overweight with a price target of $36, down from $66. The firm noted that shares of ...

In a report released today, Jason Gerberry from Bank of America Securities reiterated a Hold rating on Amphastar Pharmaceuticals (AMPH – ...

Piper Sandler adjusted its stance on Amphastar Pharmaceuticals (NASDAQ:AMPH), downgrading the company's stock rating from Overweight to Neutral and significantly reducing the price target to $36.00 ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of Amphastar Pharmaceuticals Inc (Symbol: AMPH) entered into oversold territory, hitting an RSI ...

Check the time stamp on this data. Updated AI-Generated Signals for Amphastar Pharmaceuticals Inc. (AMPH) available here: ...

Morgan Stanley upgraded Palantir (PLTR) to Equal Weight from Underweight with a price target of $95, up from $60, following ...

RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at ...

Amphastar Pharmaceuticals, Inc. (AMPH) stock price is 36.37 and Amphastar Pharmaceuticals, Inc. (AMPH) 10-day simple moving average is 36.33. Amphastar Pharmaceuticals, Inc. (AMPH) stock price is ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

View Amphastar Pharmaceuticals, Inc. (AMPH) current and estimated P/E ratio data provided by Seeking Alpha.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...